However, I think that they are generally alleging that management did not fairly represent the risk of failure of the trials and bad FDA results
Yeah, my take is they're alleging that management did not represent the risk of "adverse events", especially the "serious ones". For the class action suit to be successful, I think they'd have to prove that the "adverse events" either cause the drug to not get approved, or delay trials so therefore delay shareholders making money (and I'll keep putting in quotes because I do not believe that the skin infections and irritations were adverse events related to ZYNE's drug, as opposed to skin patches in general). I don't think either will happen, so there's no case as no shareholder will be harmed. Yes, they claim the 20% stock drop that day was the "harm to shareholders". But ZYNE isn't responsible for people shorting the stock or bailing based on not properly understanding the data (IMO). I dont think there's any chance of winning these cases, but I do very much agree with Leonard McKinley that they're having an effect on the stock. It seems that most steep drops are met with fairly significant buys, which is good. I bought more today, even though I have too much lol. Will be interesting to see where we are in 12 months.